Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV. (Q34289052)

1 August 2017

1 reference

title

Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV. (English)

1 reference

1 August 2017

1 reference

Arens M

1

1 reference

1 August 2017

publication date

1 August 2001

1 reference

Journal of Clinical Virology

1 August 2017

published in

1 reference

1 August 2017

volume

22

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

11-29

1 reference

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Pathogenesis, diagnosis and management of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Utility of early testing for HCV viremia as predictive factor of sustained response during interferon or interferon plus ribavirin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Hepatitis B virus genotypic resistance to lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Lamivudine resistance inimmunocompetent chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Rapid and sensitive genotyping of hepatitis C virus by single-strand conformation polymorphism.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Comparison of DNA enzyme immunoassay and line probe assays (Inno-LiPA HCV I and II) for hepatitis C virus genotyping.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Mutations in the cytomegalovirus UL97 gene associated with ganciclovir-resistant retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. The International HCV Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Clinical significance of hepatitis C virus genotypes.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

New Cleavase Fragment Length Polymorphism method improves the mutation detection assay

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

DNA sequencing with chain-terminating inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Herpes simplex virus type 2 meningitis in the absence of genital lesions: improved recognition with use of the polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Hepatitis C virus variants from Jakarta, Indonesia classifiable into novel genotypes in the second (2e and 2f), tenth (10a) and eleventh (11a) genetic groups

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Famciclovir in chronic hepatitis B: results of a dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

A practical approach to genetic screening for influenza virus variants

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900156-1

7 January 2021

10.1016/S1386-6532(01)00156-1

Identifiers

DOI

1 reference

1 August 2017

1 reference